So we compared these two different tau-PET tracers who are among the most used in Alzheimer’s disease research to see how the biological staging using either would compare. And we found that there, if we used head-to-head data, so all of our cohort did both MK and flortaucipir imaging, and around 70 to 80 percent of them are in the same stage using MK and flortaucipir. And around 20 to 30 percent differing on the method of biological staging, which would be either the threshold or the composite of regions we used for each biological stage, they would differ...
So we compared these two different tau-PET tracers who are among the most used in Alzheimer’s disease research to see how the biological staging using either would compare. And we found that there, if we used head-to-head data, so all of our cohort did both MK and flortaucipir imaging, and around 70 to 80 percent of them are in the same stage using MK and flortaucipir. And around 20 to 30 percent differing on the method of biological staging, which would be either the threshold or the composite of regions we used for each biological stage, they would differ. So that’s a considerable portion of people who are in different biological stages depending on the tau-PET tracer we use and that underlines the importance of a better way to harmonize different PET tracers so that we can use both for research and clinical practice without losing the correspondence between them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
